NRX Pharmaceuticals (NRXP) Stock Statistics & Valuation Metrics

NRX Pharmaceuticals has a market cap or net worth of $73.74M. The enterprise value is $31.73M.

NRX Pharmaceuticals has 33,067,630 shares outstanding. The number of shares has decreased by -2.65% in one year.

NRX Pharmaceuticals’s return on equity (ROE) is 1.80 and return on invested capital (ROIC) is 106.00%.

The current PE Ratio of NRX Pharmaceuticals is ―. NRX Pharmaceuticals’s PEG ratio is 0.05.

In the last 12 months, NRX Pharmaceuticals had revenue of 1.23M and earned -28.62M in profits. Earnings per share was -1.34.

In the last 12 months, operating cash flow was -14.11M and capital expenditures 0.00, giving a free cash flow of -14.11M billion.

NRX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

NRX Pharmaceuticals upcoming earnings date is May 19, 2026, Before Open (Confirmed).

NRX Pharmaceuticals as a current ratio of 0.31, with Debt / Equity ratio of -3.96%

In the past 12 months, NRX Pharmaceuticals has paid 0.00 in taxes.

NRX Pharmaceuticals EV to EBITDA ratio is -3.17, with an EV/FCF ratio of -3.60.

NRX Pharmaceuticals has $7.80M in cash and marketable securities with $631.00K in debt, giving a net cash position of $7.17M billion.

Gross margin is 50.61%, with operating margin of -1324.41%, and net profit margin of -2336.49%.

The average price target for NRX Pharmaceuticals is $35.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy